Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1600 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
Clarity $92m IPO For Cancer Radio-Pharmaceuticals Dr Boreham's Crucible: Clarity Pharmaceuticals Zucero: FDA Cancer Trial Approval Delays $30m IPO Federal Budget 2021: 'Patent Box', R&D, ANSTO; Comment & Response Victoria: 'Funding Returns 366% GSP, 454% Income In 10 Years' A Year In The Grass - Medical Marijuana Review Biotech Daily 1st Medical Marijuana Survey CSIRO, Doherty Distance From 'Tier 1' Sars-Cov-2 Claims
July BDI-40 Down 6%, ASX200 Up 1% Monday August 2, 2021 Still at its second highest collective market capitalization of $20,679 million, 11 companies were up, with seven up by more than 10 percent, but 28 fell, with 10 down by more than 10 percent.
The greatest losses were Polynovo down $364 million, a not unexpected Imugene retreat of $286 million, Telix down $210 million and Nanosonics down $175 million.
But the deepest fall by percentage was Oncosil, from a much smaller base, down 32.6 percent to $37 million, followed by Prescient (20.4%), Polynovo (19.5%), Actinogen (19.4%), Imugene (16.2%), Medical Developments (15.6%), Telix (12.3%), Optiscan (11.3%), Patrys (10.8%) and Amplia (10.3%).
Alterity was the best of the Top 40, from a low base up 41.4 percent to $82 million, followed by LBT up 36.4 percent to $30 million, Proteomics (29.9%), Osprey (24.2%), Dimerix (23.1%), Next Science (14.9%) and Genetic Signatures (14.0%).
The collective three Big Caps of Cochlear, CSL and Resmed passed through $200 billion to another record high, despite Cochlear’s 1.6 percent fall to $16,281 million. Resmed climbed 10.2 percent to $52,557 million, with CSL up 10.2 percent to $132,452 million, taking the collective market capitalization of the three Big Caps to $201,290 million.
The benchmark S&P ASX200 was up 1.1 percent in July to 7,393 points, and up 24.7 percent compared to 12 months ago. The three Big Caps rose 13.1 percent for the year, with the BDI-40 up 37.0 percent for the year. The Nasdaq Biotechnology Index (NBI) slipped 0.2 percent in July, but was up 21.6 percent for the year.
Outside the BDI-40, Rhinomed was the most impressive, up $14 million or 35.9 percent to $53 million, followed by Cogstate up 23.6 percent to $288 million.
The 22 companies in Cannabis Corner recovered 2.8 percent to $1,563 million, well below the record $1,973 million, but 46.6 percent higher than a year ago, with the Gina Rinehart, Thorny and Tiga backed Little Green Pharma up $25 million or 21.4 percent to $142 million, and Medlab Clinical up 30 percent to $65 million.
On the Nasdaq, Queensland’s Protagonist is the main character in the story, up a further 12.5 percent to $3,193 billion and 306.2 percent above July 31, 2020. Its most recent news was the continuation with Johnson & Johnson’s Janssen to develop IL-23 agonists for Crohn’s disease and a range of other indications.
In 2016, the University of Queensland spin-out, founded by Dr Mark Smythe, raised $US90 million to list on the Nasdaq and develop oral peptide drugs (BD: Aug 12, 2016).
Redhill with Australian assets fell 4.4 percent to $410 million, while Eyepoint (Psivida) lost 6.7 percent to $322 million. BDI-40 v S&P ASX200 Jun 30, 2006 to Jul 31, 2021
 5-Year Big Caps (Cochlear, CSL, Resmed) to Jul 31, 2021
 BDI-40 ($m) v S&P ASX200 – Jan 31, 2020 - Jul 31, 2021
(current, raw data) 
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At Jul 31, 2021
* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Cochlear
Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/.